Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytosorbents CorpCTSO · Entity 7625 | Chief Financial Officer | April 02, 2024 | April 05, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytosorbents Corp
Report date April 02, 2024 · Filed April 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 532,941 |
Reported balance
After 2024-04-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-04-02 · Grant · Acquired 65,000 · Balance 532,941 F1: These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date. F2: Includes: (i) the following RSUs, which vest as to 10,000 RSUs on the first anniversary of the date of grant, and 10,000 RSUs on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date), and will be settled into common stock, par value $0.001 per share (the "Common Stock"), upon vesting: 20,000 RSUs granted on September 18, 2023; F3: (continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon a "Change In Control" of the Company, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016 and (d) 110,000 RSUs granted on April 8, 2015; F4: (continued from footnote 3) (iii) the following RSUs, which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into Common Stock upon vesting: 18,500 RSUs granted on August 10, 2022; and F5: (continued from footnote 4) (iv) 247,941 shares of Common Stock owned by the reporting person. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.96 · Expires 2034-04-02 | Direct | 87,000 |
Reported balance
After 2024-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-02 · Grant · Acquired 87,000 · Balance 87,000 F6: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.
F2: Includes: (i) the following RSUs, which vest as to 10,000 RSUs on the first anniversary of the date of grant, and 10,000 RSUs on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date), and will be settled into common stock, par value $0.001 per share (the "Common Stock"), upon vesting: 20,000 RSUs granted on September 18, 2023;
F3: (continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon a "Change In Control" of the Company, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016 and (d) 110,000 RSUs granted on April 8, 2015;
F4: (continued from footnote 3) (iii) the following RSUs, which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into Common Stock upon vesting: 18,500 RSUs granted on August 10, 2022; and
F5: (continued from footnote 4) (iv) 247,941 shares of Common Stock owned by the reporting person.
F6: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2018 Filed May 17, 2018 01:31 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 12,400 | $4.69 | $58,156.00 |
DisclosureSEC source: 0001144204-18-029351 · tv494429_4.xml · nonDerivative · entry 1 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. Read SEC document |
| May 14, 2018 Filed May 16, 2018 18:01 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001144204-18-029163 · tv494361_4.xml · derivative · entry 4 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2023-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. Read SEC document |
| May 14, 2018 Filed May 16, 2018 18:01 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 10,000 | $8.50 | $85,000.00 |
DisclosureSEC source: 0001144204-18-029163 · tv494361_4.xml · nonDerivative · entry 2 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,304 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the 2014 Long-Term Incentive Plan (the "Plan"): (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016, (c) 110,000 RSUs granted on April 8, 2015, and (d) 8,800 RSUs granted on March 15, 2018, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 10,938 of the RSUs granted to the reporting person on February 24, 2017 and unvested, (b) 7,000 of the RSUs granted on June 7, 2016 and unvested,and (c) 23,134 RSUs granted on February 28, 2018 and unvested and (iii) 30,732 shares of common stock owned by the reporting person. Read SEC document |
| May 14, 2018 Filed May 16, 2018 18:01 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 10,000 | $2.90 | $29,000.00 |
DisclosureSEC source: 0001144204-18-029163 · tv494361_4.xml · nonDerivative · entry 1 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 01:35 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (Right to Buy) · Derivative | 120 | $0.00 Strike: $4.69 | $0.00 |
DisclosureSEC source: 0001144204-18-021234 · tv491396_4.xml · derivative · entry 4 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,800 Underlying: Common Stock · 120 shares Expires 2026-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 01:35 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 120 | $8.25 | $990.00 |
DisclosureSEC source: 0001144204-18-021234 · tv491396_4.xml · nonDerivative · entry 2 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,304 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the 2014 Long-Term Incentive Plan (the "Plan"): (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016, (c) 110,000 RSUs granted on April 8, 2015, and (d) 8,800 RSUs granted on March 15, 2018, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 10,938 of the RSUs granted to the reporting person on February 24, 2017 and unvested, (b) 7,000 of the RSUs granted on June 7, 2016 and unvested, and (c) 23,134 RSUs granted on February 28, 2018 and unvested and (iii) 30,732 shares of common stock owned by the reporting person. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 01:35 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 120 | $4.69 | $562.80 |
DisclosureSEC source: 0001144204-18-021234 · tv491396_4.xml · nonDerivative · entry 1 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 14:18 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,176 | $0.00 Strike: $4.69 | $0.00 |
DisclosureSEC source: 0001144204-18-015453 · tv488826_4.xml · derivative · entry 4 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,920 Underlying: Common Stock · 11,176 shares Expires 2026-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 14:18 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 11,176 | $8.25 | $92,202.00 |
DisclosureSEC source: 0001144204-18-015453 · tv488826_4.xml · nonDerivative · entry 2 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,070 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. F2 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of the Company, as defined in the Plan: (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016 and (c) 110,000 RSUs granted on April 8, 2015, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 10,938 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof , (b) 7,000 of the RSUs granted on June 7, 2016 and unvested as of the date hereof, and (c) 34,700 RSUs granted on February 28, 2018 and (iii) 24,732 shares of common stock owned by the reporting person. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 14:18 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 11,176 | $4.69 | $52,415.44 |
DisclosureSEC source: 0001144204-18-015453 · tv488826_4.xml · nonDerivative · entry 1 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 15:01 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 93,500 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001144204-18-015764 · tv488962_4.xml · derivative · entry 3 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,500 Underlying: Common Stock · 93,500 shares Expires 2028-03-15 F4 · derivative.exercise_date: Such options were granted pursuant to the Plan, and shall vest upon achievement of certain performance goals as determined in the discretion of the Board of Directors of the Company. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 15:01 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantCommon Stock | 8,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-015764 · tv488962_4.xml · nonDerivative · entry 1 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,870 F1 · shares: These shares represent restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"). F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company: (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016, (c) 110,000 RSUs granted on April 8, 2015, and (d) 8,800 RSUs granted on March 15, 2018 and reported on this Form 4, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 10,938 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof , (b) 7,000 of the RSUs granted on June 7, 2016 and unvested as of the date hereof, and (c) 34,700 RSUs granted on February 28, 2018 and (iii) 24,732 shares of common stock owned by the reporting person. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 17:28 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,104 | $0.00 Strike: $4.69 | $0.00 |
DisclosureSEC source: 0001144204-18-014852 · tv488571_4.xml · derivative · entry 4 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,096 Underlying: Common Stock · 1,104 shares Expires 2026-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 17:28 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 1,104 | $8.25 | $9,108.00 |
DisclosureSEC source: 0001144204-18-014852 · tv488571_4.xml · nonDerivative · entry 2 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,070 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. F2 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of the Company, as defined in the Plan: (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016 and (c) 110,000 RSUs granted on April 8, 2015, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 10,938 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof , (b) 7,000 of the RSUs granted on June 7, 2016 and unvested as of the date hereof, and (c) 34,700 RSUs granted on February 28, 2018 and (iii) 24,732 shares of common stock owned by the reporting person. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 17:28 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 1,104 | $4.69 | $5,177.76 |
DisclosureSEC source: 0001144204-18-014852 · tv488571_4.xml · nonDerivative · entry 1 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 23:44 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 75,650 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001144204-18-012635 · tv487682_form4.xml · derivative · entry 3 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,650 Underlying: Common Stock · 75,650 shares Expires 2027-02-24 F1 · derivative.exercise_date: On February 24, 2017, the reporting person was granted an option to purchase 89,000 shares of Common Stock pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan ("Plan"), which was to vest upon achievement of certain performance goals as determined in the discretion of the Compensation Committee of the Board of Directors of CytoSorbents Corporation (the "Company"). This grant was reported on a Form 4 filed on February 28, 2017. On February 28, 2018, the Compensation Committee of the Board of Directors of the Company determined that 85% of such performance criteria was achieved during 2017, resulting in vesting of 75,650 shares underlying this option. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 23:44 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantCommon Stock | 34,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-012635 · tv487682_form4.xml · nonDerivative · entry 1 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,070 F2 · shares: These shares represent restricted stock units which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. F3 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of the Company, as defined in the Plan: (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016 and (c) 110,000 RSUs granted on April 8, 2015, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 10,938 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof , (b) 7,000 of the RSUs granted on June 7, 2016 and unvested as of the date hereof, and (c) 34,700 RSUs granted on February 28, 2018 and reported on this Form 4 and (iii) 24,732 shares of common stock owned by the reporting person. Read SEC document |
| February 21, 2018 Filed Apr 5, 2018 23:14 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001144204-18-019461 · tv490542_4.xml · derivative · entry 4 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2023-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. Read SEC document |
| February 21, 2018 Filed Apr 5, 2018 23:14 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 10,000 | $8.00 | $80,000.00 |
DisclosureSEC source: 0001144204-18-019461 · tv490542_4.xml · nonDerivative · entry 2 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,870 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the 2014 Long-Term Incentive Plan (the "Plan"): (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016, (c) 110,000 RSUs granted on April 8, 2015, and (d) 8,800 RSUs granted on March 15, 2018, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 10,938 of the RSUs granted to the reporting person on February 24, 2017 and unvested, (b) 7,000 of the RSUs granted on June 7, 2016 and unvested, and (c) 23,134 RSUs granted on February 28, 2018 and unvested and (iii) 30,607 shares of common stock owned by the reporting person. F3 · balance_after: Reflects securities owned by the reporting person as of the date of filing of this Form 4. Read SEC document |
| February 21, 2018 Filed Apr 5, 2018 23:14 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 10,000 | $2.90 | $29,000.00 |
DisclosureSEC source: 0001144204-18-019461 · tv490542_4.xml · nonDerivative · entry 1 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. Read SEC document |
| January 12, 2018 Filed Jan 18, 2018 00:59 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,400 | $0.00 Strike: $4.69 | $0.00 |
DisclosureSEC source: 0001144204-18-002522 · tv483528_4.xml · derivative · entry 4 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,200 Underlying: Common Stock · 12,400 shares Expires 2026-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. Read SEC document |
| January 12, 2018 Filed Jan 18, 2018 00:59 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 12,400 | $7.75 | $96,100.00 |
DisclosureSEC source: 0001144204-18-002522 · tv483528_4.xml · nonDerivative · entry 2 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,638 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. F2 · balance_after: Includes (i) the following restricted stock units that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 15,700 restricted stock units granted on February 24, 2017, (b) 47,000 restricted stock units granted on June 7, 2016 and (c) 110,000 restricted stock units granted on April 8, 2015, (ii) the following restricted stock units subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 32,813 restricted stock units granted on February 24, 2017 and (b) 21,000 restricted stock units granted on June 7, 2016 and (iii) 2,125 shares of common stock owned by the reporting person. Read SEC document |
| January 12, 2018 Filed Jan 18, 2018 00:59 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 12,400 | $4.69 | $58,156.00 |
DisclosureSEC source: 0001144204-18-002522 · tv483528_4.xml · nonDerivative · entry 1 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. Read SEC document |
| January 08, 2018 Filed Jan 11, 2018 02:50 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,400 | $0.00 Strike: $4.69 | $0.00 |
DisclosureSEC source: 0001144204-18-001799 · tv483029_4.xml · derivative · entry 8 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,600 Underlying: Common Stock · 12,400 shares Expires 2026-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. Read SEC document |
| January 08, 2018 Filed Jan 11, 2018 02:50 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001144204-18-001799 · tv483029_4.xml · derivative · entry 7 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2023-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. Read SEC document |
| January 08, 2018 Filed Jan 11, 2018 02:50 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 10,000 | $7.50 | $75,000.00 |
DisclosureSEC source: 0001144204-18-001799 · tv483029_4.xml · nonDerivative · entry 5 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,638 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. F2 · balance_after: Includes (i) the following restricted stock units that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 15,700 restricted stock units granted on February 24, 2017, (b) 47,000 restricted stock units granted on June 7, 2016 and (c) 110,000 restricted stock units granted on April 8, 2015, (ii) the following restricted stock units subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 32,813 restricted stock units granted on February 24, 2017 and (b) 21,000 restricted stock units granted on June 7, 2016 and (iii) 2,125 shares of common stock owned by the reporting person. Read SEC document |
| January 08, 2018 Filed Jan 11, 2018 02:50 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 12,400 | $7.25 | $89,900.00 |
DisclosureSEC source: 0001144204-18-001799 · tv483029_4.xml · nonDerivative · entry 4 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,638 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. Read SEC document |
| January 08, 2018 Filed Jan 11, 2018 02:50 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 10,000 | $7.15 | $71,500.00 |
DisclosureSEC source: 0001144204-18-001799 · tv483029_4.xml · nonDerivative · entry 3 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,038 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. Read SEC document |
| January 08, 2018 Filed Jan 11, 2018 02:50 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 12,400 | $4.69 | $58,156.00 |
DisclosureSEC source: 0001144204-18-001799 · tv483029_4.xml · nonDerivative · entry 2 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. Read SEC document |
| January 08, 2018 Filed Jan 11, 2018 02:50 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 20,000 | $2.90 | $58,000.00 |
DisclosureSEC source: 0001144204-18-001799 · tv483029_4.xml · nonDerivative · entry 1 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017. Read SEC document |
| May 15, 2017 Filed May 16, 2017 22:00 UTC | Cytosorbents Corp CTSO · Entity 7625 | PurchaseCommon Stock | 1,000 | $4.34 | $4,340.60 |
DisclosureSEC source: 0001144204-17-028016 · v467237_form4.xml · nonDerivative · entry 1 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,000 F1 · ownership.nature: These shares are held by the reporting person's husband in a 401(k) account and, as such, the reporting person may be deemed the beneficial owner of such shares. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 22:21 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 89,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001144204-17-011840 · v460708_4.xml · derivative · entry 4 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,000 Underlying: Common Stock · 89,000 shares Expires 2027-02-24 F6 · derivative.exercise_date: Such options were granted pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, and shall vest upon achievement of certain performance goals as determined in the discretion of the Board of Directors of CytoSorbents Corporation. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 22:21 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantCommon Stock | 15,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-011840 · v460708_4.xml · nonDerivative · entry 2 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,638 F3 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan. F4 · balance_after: Includes (i) 15,700 restricted stock units granted on February 24, 2017 and reported on this Form 4, (ii) 47,000 restricted stock units granted on June 7, 2016, subject to vesting in accordance with the schedule set forth in (3) above, (iii) 110,000 restricted stock units granted on April 8, 2015, subject to vesting in accordance with the schedule set forth in (3) above and (iv) the restricted stock units described in (2) above. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 22:21 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantCommon Stock | 32,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-011840 · v460708_4.xml · nonDerivative · entry 1 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,938 F1 · shares: These shares represent restricted stock units which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. F2 · balance_after: Includes (i) 32,813 restricted stock units granted on February 24, 2017 and reported on this Form 4, (ii) 21,000 restricted stock units granted on June 7, 2016, subject to vesting in accordance with the schedule set forth in (1) above and (iii) 2,125 shares of common stock owned by the reporting person. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 20:51 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 62,000 | $0.00 Strike: $4.69 | $0.00 |
DisclosureSEC source: 0001144204-17-005341 · v458129_4.xml · derivative · entry 1 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2026-06-07 F1 · derivative.exercise_date: On June 7, 2016, the reporting person was granted an option to purchase 77,500 shares of common stock pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, which was to vest upon achievement of certain performance goals as determined in the discretion of the Board of Directors of CytoSorbents Corporation (the "Company"). This grant was reported on a Form 4 filed on June 9, 2016. On January 30, 2017, the Board of Directors of the Company determined that 80% of such performance criteria was achieved during 2016, resulting in the vesting of 62,000 shares underlying this option. Read SEC document |
| December 06, 2016 Filed Dec 7, 2016 22:25 UTC | Cytosorbents Corp CTSO · Entity 7625 | PurchaseCommon Stock | 1,000 | $4.83 | $4,829.20 |
DisclosureSEC source: 0001144204-16-138422 · v454630_4.xml · nonDerivative · entry 1 BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,000 F1 · ownership.nature: The shares are held by the reporting person's husband in a 401(k) account, and as such, the reporting person may be deemed the beneficial owner of such shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.